Skip to main content
SpringerLink
Log in

Nilotinib provides better outcomes at lower cost in Ph+ CML-CP

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study, which was presented at the 57th Annual Meeting and Exposition of the American Society of Hematology, was sponsored by Novartis Pharmaceuticals Corporation.

Reference

  • Li N, et al. Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data. 57th Annual Meeting and Exposition of the American Society of Hematology : abstr. 2090, 5 Dec 2015. Available from: URL: https://ash.confex.com/ash/2015/webprogram/Paper83023.html

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nilotinib provides better outcomes at lower cost in Ph+ CML-CP. PharmacoEcon Outcomes News 745, 23 (2016). https://doi.org/10.1007/s40274-016-2764-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-2764-3

Search

Navigation